NEW YORK – The makeup of patients' microbiomes can predict their clinical outcomes when undergoing stem cell transplants.

Allogeneic hematopoietic stem cell transplants are common among patients with blood cancers, and while they may cure the disease, such transplants can also lead to complications such as graft-versus-host disease and infections. Previous research has suggested there are links between the gut microbiome and such adverse outcomes, but those studies were largely limited to single centers.